Targeting macrophagic PIM-1 alleviates osteoarthritis by inhibiting NLRP3 inflammasome activation via suppressing mitochondrial ROS/Cl− efflux signaling pathway

[1]  Yong-jie Wei,et al.  Advances in understanding mechanisms underlying mitochondrial structure and function damage by ozone. , 2022, The Science of the total environment.

[2]  Gabriel Núñez,et al.  The NLRP3 inflammasome: activation and regulation. , 2022, Trends in biochemical sciences.

[3]  A. Saviano,et al.  Analysis of rheumatoid- vs psoriatic arthritis synovial fluid reveals differential macrophage (CCR2) and T helper subsets (STAT3/4 and FOXP3) activation. , 2022, Autoimmunity reviews.

[4]  Xiaopan Chen,et al.  Inhibition of CEBPB Attenuates Lupus Nephritis via Regulating Pim-1 Signaling , 2022, Mediators of inflammation.

[5]  Feng Liu,et al.  Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate osteoarthritis of the knee in mice model by interacting with METTL3 to reduce m6A of NLRP3 in macrophage , 2022, Stem Cell Research & Therapy.

[6]  N. Lane,et al.  Synovial inflammation in osteoarthritis progression , 2022, Nature Reviews Rheumatology.

[7]  D. Shi,et al.  Targeting macrophagic SHP2 for ameliorating osteoarthritis via TLR signaling , 2022, Acta pharmaceutica Sinica. B.

[8]  Xiaolei Zhang,et al.  Itaconate attenuates osteoarthritis by inhibiting STING/NF-κB axis in chondrocytes and promoting M2 polarization in macrophages. , 2022, Biochemical pharmacology.

[9]  Masafumi Takahashi,et al.  Loop Between NLRP3 Inflammasome and Reactive Oxygen Species. , 2021, Antioxidants & redox signaling.

[10]  T. Maher,et al.  Enhanced IL-1β Release Following NLRP3 and AIM2 Inflammasome Stimulation Is Linked to mtROS in Airway Macrophages in Pulmonary Fibrosis , 2021, Frontiers in Immunology.

[11]  J. Isaacs,et al.  Pim Kinases as Therapeutic Targets in Early Rheumatoid Arthritis , 2021, Arthritis & rheumatology.

[12]  C. Svensson,et al.  Cell-cell interactions in joint pain: rheumatoid arthritis and osteoarthritis. , 2021, Pain.

[13]  Y. Henrotin,et al.  The Damage-Associated Molecular Patterns (DAMPs) as Potential Targets to Treat Osteoarthritis: Perspectives From a Review of the Literature , 2021, Frontiers in Medicine.

[14]  Yumeng Cao,et al.  PIM1 inhibition attenuated endotoxin-induced acute lung injury through modulating ELK3/ICAM1 axis on pulmonary microvascular endothelial cells , 2020, Inflammation Research.

[15]  Geun-Shik Lee,et al.  Riboflavin, vitamin B2, attenuates NLRP3, NLRC4, AIM2, and non-canonical inflammasomes by the inhibition of caspase-1 activity , 2020, Scientific Reports.

[16]  T. Kwon,et al.  Anti-Inflammatory Effects of the Novel PIM Kinase Inhibitor KMU-470 in RAW 264.7 Cells through the TLR4-NF-κB-NLRP3 Pathway , 2020, International journal of molecular sciences.

[17]  Lin Chen,et al.  SQSTM1-dependent autophagic degradation of PKM2 inhibits the production of mature IL1B/IL-1β and contributes to LIPUS-mediated anti-inflammatory effect , 2020, Autophagy.

[18]  Yumeng Cao,et al.  Inhibition of PIM1 kinase attenuates bleomycin-induced pulmonary fibrosis in mice by modulating the ZEB1/E-cadherin pathway in alveolar epithelial cells. , 2020, Molecular immunology.

[19]  P. Héroux,et al.  Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway , 2020, Cellular & Molecular Immunology.

[20]  Zilin Li,et al.  Structural Mechanism for GSDMD Targeting by Autoprocessed Caspases in Pyroptosis , 2020, Cell.

[21]  H. Whitaker,et al.  PIM kinase inhibition: co-targeted therapeutic approaches in prostate cancer , 2020, Signal Transduction and Targeted Therapy.

[22]  David F. Kashatus,et al.  PIM kinases alter mitochondrial dynamics and chemosensitivity in lung cancer , 2019, bioRxiv.

[23]  F. Berenbaum,et al.  Danger signals and inflammaging in osteoarthritis. , 2019, Clinical and experimental rheumatology.

[24]  N. Yang,et al.  Pim‐1 as a Therapeutic Target in Lupus Nephritis , 2019, Arthritis & rheumatology.

[25]  J. Ting,et al.  The NLRP3 inflammasome: molecular activation and regulation to therapeutics , 2019, Nature Reviews Immunology.

[26]  H. Qiao,et al.  Kinsenoside attenuates osteoarthritis by repolarizing macrophages through inactivating NF-κB/MAPK signaling and protecting chondrocytes , 2019, Acta pharmaceutica Sinica. B.

[27]  Chengqi He,et al.  Pro-inflammatory cytokines: The link between obesity and osteoarthritis. , 2018, Cytokine & growth factor reviews.

[28]  G. López-Castejón,et al.  Chloride regulates dynamic NLRP3-dependent ASC oligomerization and inflammasome priming , 2018, Proceedings of the National Academy of Sciences.

[29]  S. Wang,et al.  NLRP3 inflammasome activation contributes to the pathogenesis of rheumatoid arthritis , 2018, Clinical and experimental immunology.

[30]  Feihu Chen,et al.  The role of Ca2+ in acid-sensing ion channel 1a-mediated chondrocyte pyroptosis in rat adjuvant arthritis , 2018, Laboratory Investigation.

[31]  E. Lee,et al.  PIM-1 kinase is a novel regulator of proinflammatory cytokine-mediated responses in rheumatoid arthritis fibroblast-like synoviocytes , 2018, Rheumatology.

[32]  E. Latz,et al.  Targeting the NLRP3 inflammasome in inflammatory diseases , 2018, Nature Reviews Drug Discovery.

[33]  D. Gibson,et al.  NLRP3 as a potentially novel biomarker for the management of osteoarthritis. , 2018, Osteoarthritis and cartilage.

[34]  T. Assimes,et al.  Hypermetabolic macrophages in rheumatoid arthritis and coronary artery disease due to glycogen synthase kinase 3b inactivation , 2018, Annals of the rheumatic diseases.

[35]  L. O’Neill,et al.  Metabolic regulation of NLRP3 , 2018, Immunological reviews.

[36]  J. Cui,et al.  CLICs-dependent chloride efflux is an essential and proximal upstream event for NLRP3 inflammasome activation , 2017, Nature Communications.

[37]  M. Karin,et al.  Limiting inflammation—the negative regulation of NF-κB and the NLRP3 inflammasome , 2017, Nature Immunology.

[38]  G. Núñez,et al.  Mechanism and Regulation of NLRP3 Inflammasome Activation. , 2016, Trends in biochemical sciences.

[39]  C. Pineda,et al.  The Overexpression of NALP3 Inflammasome in Knee Osteoarthritis Is Associated with Synovial Membrane Prolidase and NADPH Oxidase 2 , 2016, Oxidative medicine and cellular longevity.

[40]  Carlos Ortiz-de-Solorzano,et al.  The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care , 2016, Clinical Cancer Research.

[41]  Chuan-Qi Zhong,et al.  Gasdermin D is an executor of pyroptosis and required for interleukin-1β secretion , 2015, Cell Research.

[42]  Thomas Pap,et al.  Cartilage damage in osteoarthritis and rheumatoid arthritis—two unequal siblings , 2015, Nature Reviews Rheumatology.

[43]  T. Cai,et al.  Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death , 2015, Nature.

[44]  Mark A Sussman,et al.  Cell and gene therapy for severe heart failure patients: The time and place for Pim-1 kinase , 2013, Expert review of cardiovascular therapy.

[45]  P. Low,et al.  Direct in vivo evidence of activated macrophages in human osteoarthritis. , 2013, Osteoarthritis and cartilage.

[46]  Jos W. M. van der Meer,et al.  Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.

[47]  A. So,et al.  Microcrystals as DAMPs and their role in joint inflammation. , 2012, Rheumatology.

[48]  C. Little,et al.  The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. , 2010, Osteoarthritis and cartilage.

[49]  T. Brunner,et al.  IL-3 induces a Pim1-dependent antiapoptotic pathway in primary human basophils. , 2008, Blood.

[50]  Kyu-Tae Kim,et al.  Constitutively activated FLT3 phosphorylates BAD partially through Pim‐1 , 2006, British journal of haematology.

[51]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[52]  C. Thompson,et al.  The survival kinases Akt and Pim as potential pharmacological targets. , 2005, The Journal of clinical investigation.

[53]  J. Ihle,et al.  Induction of tyrosine phosphorylation of Vav and expression of Pim-1 correlates with Jak2-mediated growth signaling from the erythropoietin receptor. , 1994, Blood.

[54]  T. Le,et al.  Sustained expression of the pim-1 kinase is specifically induced in myeloid cells by cytokines whose receptors are structurally related. , 1992, Oncogene.

[55]  G. Jay,et al.  The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model. , 2015, Osteoarthritis and cartilage.

[56]  Johanne Martel-Pelletier,et al.  Role of proinflammatory cytokines in the pathophysiology of osteoarthritis , 2011, Nature Reviews Rheumatology.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..